BACKGROUND Research targeting glycosylated hemoglobin A1c (HbA 1c ) to <6.5% to prevent coronary heart disease
In 2 independent populations, we have observed that participants with both the Hp2-2 genotype (homozygous for presence of CNV) and HbA 1c $6.5% had a 10-fold higher risk of coronary heart disease (CHD) compared with those with at least 1 Hp1 allele and HbA 1c <6.5% (12) . However, a recent analysis of cardiovascular disease among adults in the Bruneck study did not observe a similar association (13) . The discrepancy may be due to several study design factors, especially the combined endpoint of CHD and stroke (the majority of cases were stroke), because stroke has been associated with the Hp1-1 genotype rather than the Hp2-2 genotype (14, 15) . However, the Bruneck study is of interest because it contained repeated measures of HbA 1c and provides suggestive evidence for a potential time-dependent bias against the Hp2-2 genotype as participants aged that supports previous findings of increased longevity among individuals with the Hp1-1 genotype (16, 17) . Thus, if Hp2-2 individuals are at increased risk of early disease and death, it strengthens the growing evidence behind the hypothesis that targeted screening and treatment for the Hp2-2 genotype in cases of HbA 1c $6.5% could prevent coronary events.
In the present study, we used a large prospective case-control study nested within a cohort of healthy men at baseline to further examine the interaction between the Hp polymorphism and HbA 1c concentration on risk of CHD, testing the hypothesis that targeted screening for the Hp2-2 genotype in the setting of HbA 1c $6.5% may be prudent. Because previous long-term studies have reported that the association between HbA 1c and the risk of CHD is strongest in the earliest years of follow-up (18), we examined the first and second halves of follow-up separately as well as together. We then sought replication of our full analysis in a complementary, but independent, cohort of women. Cahill et al. (20) . Details of the genotype frequencies and baseline characteristics of the specific sample used in this present study have been previously reported (12) , but the hypothesis tested is new in the present study. Using 2-tailed tests, the type I error probability of 0.05, a prevalence in control participants of 0.39 for the Hp2-2 genotype, and our final NHS sample size of 400 cases matched 1:1 to control participants, we have >80% power to detect an odds ratio of 1.50. (18), we conducted analyses within halves of follow-up (first 8 years and second 8 years), in addition to examining the full follow-up period. To pool the risk estimates from multiple study cohorts, we used the weighted average of regression estimates in a randomeffects meta-analysis, and tested for between-study heterogeneity (31). All analyses were conducted using SAS software version 9.3 (SAS Institute, Cary, North Carolina), at a 2-tailed alpha level of 0.05.
RESULTS
The distribution of Hp genotype frequencies in the HPFS cohort was 16% (Hp1-1), 45% (Hp2-1), and 39% (Hp2-2). The Hp genotype frequency did not differ between cases and control participants. Baseline characteristics by case-control status are described in Table 1 . As expected, cases drank less alcohol and had a lower diet quality than control participants, and had higher body mass index, family history of CHD prevalence of hypertension, diabetes, hypercholesterolemia, and greater medication use at baseline. by the replication of these findings in women, using data from a second cohort.
In 2 independent cohorts with a broad range The multivariate model is adjusted for matching factors (age and smoking) and also: body mass index, alcohol, physical activity, parental coronary heart disease before the age of 60 years, diet quality score, history of high cholesterol, history of high blood pressure, and medications for high blood pressure. HbA 1c , Hp2-2 Genotype, and Coronary Disease O C T O B E R 2 0 , 2 0 1 5 : 1 7 9 1 -9
